Barbara Ensoli, MD
6
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
1 terminated/withdrawn out of 6 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine
Role: lead
Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects
Role: lead
Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients
Role: lead
Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects
Role: lead
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Role: lead
A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers
Role: lead
All 6 trials loaded